Physician profile
Amer Rafiaa
NPI 1427022656
$7,180.57
in general payments reported to CMS, 2019-2025
36 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $1,096 · 2021: $2,252 · 2022: $824 · 2023: $635 · 2024: $304 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917 · Education: $221 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.03 |
| Education | $220.90 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,767.46 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $874.94 | 2019-2023 | Jardiance |
| Amgen INC. | $469.74 | 2021-2022 | |
| Pfizer INC. | $381.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $381.15 | 2019-2025 | Keytruda |
| Janssen Biotech, INC. | $331.42 | 2019-2024 | Darzalex, Talvey, Tecvayli |
| Astellas Pharma US INC | $272.48 | 2019-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $269.91 | 2019-2022 | |
| Genzyme Corporation | $261.11 | 2019-2025 | |
| Celgene Corporation | $256.15 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $210.63 | 2020-2025 | Padcev, Tukysa, Adcetris |
| Lilly USA, LLC | $205.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.96 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $173.92 | 2019 | |
| Gilead Sciences, INC. | $136.61 | 2019-2023 | Trodelvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $128.83 | 2019-2025 | Enhertu |
| Dova Pharmaceuticals | $107.41 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $104.38 | 2020-2022 | |
| Taiho Oncology, INC. | $97.55 | 2019-2021 | |
| Puma Biotechnology, INC. | $89.84 | 2019-2020 | |
| Incyte Corporation | $77.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $57.70 | 2020-2021 | |
| Kite Pharma, INC. | $49.22 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $46.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.77 | 2019-2020 | |
| Emmaus Medical, INC. | $29.01 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $25.68 | 2025 | Pyrukynd |
| Array Biopharma INC | $23.08 | 2020 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Allergan, INC. | $19.80 | 2019 | |
| Karyopharm Therapeutics INC. | $18.91 | 2020 | |
| Sumitomo Pharma America, INC. | $17.35 | 2023 | Orgovyx |
| Secura Bio, INC. | $15.14 | 2019 | |
| Exact Sciences Corporation | $13.81 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $11.71 | 2022 | |
| Clovis Oncology, INC. | $10.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Rafiaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.